acute myeloid leukemia (AML)

Catherine J. Lee, MD

Lee, Catherine

Associate Professor of Medicine in the Division of Hematology/BMT

Huntsman Cancer Center, University of Utah

Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials.

Online Profile:

Catherine J. Lee, MD

Aplastic Anemia, MDS, and PNH Virtual Support Group - 2022 July

Event Date:

Sat, 07/23/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Bone Marrow Disease(s):

2022 San Antonio, TX, Patient and Family Virtual Conference

View each session from the San Antonio Patient and Family Virtual Conference with the links below:

Event Date:

Sat, 03/26/2022 - 9:00am (EDT)

Conference Materials:

Final-3-26-22 MDS to AML -AAMDIF talk (1).pdf

Paroxysmal Nocturnal Hemoglobinuria (PNH) Karnad (2) San Antonio.pdf

MPN-MDS Overlap R Mesa 2022 (1).pdf

Aplastic Anemia San Antonio Conference.pdf

UT San Antonio March 2022 Wellness (1).pdf

Bone Marrow Disease(s):

Conference Event Type:

Patient and Family - Regional One Day

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

June 2, 2022

- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –

Aplastic Anemia, MDS, and PNH Virtual Support Group - 2022 June

Event Date:

Sat, 06/25/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Bone Marrow Disease(s):

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with

MDS to AML - 2022 San Antonio Patient & Family Virtual Conference

In this conference session, Dr. Amer Zeidan, MD discusses understanding the management options for higher risk MDS, the evolution of MDS to AML and more.

Living With Bone Marrow Failure Diseases - 2022 San Antonio Patient & Family Virtual Conference

In this conference session, Dr. Krisstina Gowin DO discusses best practices when living with

Aplastic Anemia, MDS, and PNH Virtual Support Group

Event Date:

Sat, 05/28/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Bone Marrow Disease(s):

The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator

PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.”

Search form

acute myeloid leukemia (AML)